- Conditions
- Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Interventions
- Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
- Drug
- Lead sponsor
- Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
- Federal
- Eligibility
- Not listed
- Enrollment
- 8,680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 49
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Interventions
- [18F]APN-1607
- Drug
- Lead sponsor
- APRINOIA Therapeutics, LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Mount Arlington, New Jersey • New York, New York
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
- Interventions
- Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
- Biological
- Lead sponsor
- Steven E Arnold, MD
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia, Cognitive Decline, Dementia, Alzheimer Type
- Interventions
- Renew NCP-5
- Device
- Lead sponsor
- Renew Research, LLC
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Irvine, California • Lady Lake, Florida + 7 more
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
- Interventions
- repetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation rTMS
- Device · Other
- Lead sponsor
- Chi-Ying (Roy) Lin
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Nicotinamide, Placebo Comparator
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Irvine, California • Los Angeles, California
- Conditions
- Alzheimer Disease
- Interventions
- E2814
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- La Jolla, California • Indianapolis, Indiana
- Conditions
- Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
- Interventions
- Audiologist-based fitting, Service-only Fitting, Device-only fitting
- Device
- Lead sponsor
- Yu-Hsiang Wu
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Nashville, Tennessee
- Conditions
- Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
- Interventions
- No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
- Device · Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- ACU193, Placebo
- Drug
- Lead sponsor
- Acumen Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Anaheim, California • Newport Beach, California + 14 more
- Conditions
- Alzheimer's Disease
- Interventions
- VX-745
- Drug
- Lead sponsor
- EIP Pharma Inc
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Alzheimer's Disease
- Interventions
- Photobiomodulation
- Device
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
- Interventions
- Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dementia, Alzheimer Type
- Interventions
- Xanamem™, Placebo (for Xanamem™)
- Drug
- Lead sponsor
- Actinogen Medical
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Poway, California + 11 more
- Conditions
- Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Leronlimab (700mg)
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Interventions
- Pioglitazone, Pioglitazone placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 65 Years to 83 Years
- Enrollment
- 3,494 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
- Conditions
- Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
- Interventions
- F 18 T807
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Canakinumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Charlestown, Massachusetts • Stony Brook, New York
- Conditions
- Alzheimer Disease
- Interventions
- LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
- Drug
- Lead sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
- Conditions
- Alzheimer Disease
- Interventions
- LY3002813-IV, LY3002813-SC, Placebo-IV
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Long Beach, California • Orlando, Florida • Atlanta, Georgia + 1 more
- Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
- Interventions
- BIIB080, BIIB080-matching placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- ABT-957, Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 9
- States / cities
- Cypress, California • Orlando, Florida • The Villages, Florida + 6 more
- Conditions
- Cognitive Dysfunction, Dementia, Mild
- Interventions
- FitMi AD, Conventional exercise program
- Device · Other
- Lead sponsor
- Flint Rehabilitation Devices, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Downey, California